Topical prostaglandin E2 and chemo- and radio-induced oral mucositis

Report on 15 cases

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Oral mucositis is a frequent complication of specific antineoplastic treatments. Mouth lesions have a great impact on the quality of life of cancer patients. Current topical and systemic therapies have not yet achieved completely satisfactory results. We studied the effect of topical use of prostaglandin E2 (PGE2) 2.25 mg/day on oral mucositis of 15 chemo- or radio-treated cancer patients. Absolute mean VAS value on mouth pain decreased from 71.2 at T0, to 34.1 at T3 (p <0.001) and to 14.1 at T6 (p <0.001). Objective evaluation according to Miller scale showed significant improvement at day 3 and 6, as well. We suggest that PGE2 could be a useful additional therapeutic agent to palliate oral symptoms.

Original languageEnglish
Pages (from-to)205-208
Number of pages4
JournalOncology Reports
Volume3
Issue number1
Publication statusPublished - 1996

Fingerprint

Stomatitis
Radio
Dinoprostone
Mouth
Antineoplastic Agents
Neoplasms
Therapeutics
Quality of Life
Pain

Keywords

  • mouth care
  • oral mucositis
  • prostaglandins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Topical prostaglandin E2 and chemo- and radio-induced oral mucositis : Report on 15 cases. / Maltoni, Marco.

In: Oncology Reports, Vol. 3, No. 1, 1996, p. 205-208.

Research output: Contribution to journalArticle

@article{c1608b7585af43f6a641d60c626fb409,
title = "Topical prostaglandin E2 and chemo- and radio-induced oral mucositis: Report on 15 cases",
abstract = "Oral mucositis is a frequent complication of specific antineoplastic treatments. Mouth lesions have a great impact on the quality of life of cancer patients. Current topical and systemic therapies have not yet achieved completely satisfactory results. We studied the effect of topical use of prostaglandin E2 (PGE2) 2.25 mg/day on oral mucositis of 15 chemo- or radio-treated cancer patients. Absolute mean VAS value on mouth pain decreased from 71.2 at T0, to 34.1 at T3 (p <0.001) and to 14.1 at T6 (p <0.001). Objective evaluation according to Miller scale showed significant improvement at day 3 and 6, as well. We suggest that PGE2 could be a useful additional therapeutic agent to palliate oral symptoms.",
keywords = "mouth care, oral mucositis, prostaglandins",
author = "Marco Maltoni",
year = "1996",
language = "English",
volume = "3",
pages = "205--208",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Topical prostaglandin E2 and chemo- and radio-induced oral mucositis

T2 - Report on 15 cases

AU - Maltoni, Marco

PY - 1996

Y1 - 1996

N2 - Oral mucositis is a frequent complication of specific antineoplastic treatments. Mouth lesions have a great impact on the quality of life of cancer patients. Current topical and systemic therapies have not yet achieved completely satisfactory results. We studied the effect of topical use of prostaglandin E2 (PGE2) 2.25 mg/day on oral mucositis of 15 chemo- or radio-treated cancer patients. Absolute mean VAS value on mouth pain decreased from 71.2 at T0, to 34.1 at T3 (p <0.001) and to 14.1 at T6 (p <0.001). Objective evaluation according to Miller scale showed significant improvement at day 3 and 6, as well. We suggest that PGE2 could be a useful additional therapeutic agent to palliate oral symptoms.

AB - Oral mucositis is a frequent complication of specific antineoplastic treatments. Mouth lesions have a great impact on the quality of life of cancer patients. Current topical and systemic therapies have not yet achieved completely satisfactory results. We studied the effect of topical use of prostaglandin E2 (PGE2) 2.25 mg/day on oral mucositis of 15 chemo- or radio-treated cancer patients. Absolute mean VAS value on mouth pain decreased from 71.2 at T0, to 34.1 at T3 (p <0.001) and to 14.1 at T6 (p <0.001). Objective evaluation according to Miller scale showed significant improvement at day 3 and 6, as well. We suggest that PGE2 could be a useful additional therapeutic agent to palliate oral symptoms.

KW - mouth care

KW - oral mucositis

KW - prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0030034517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030034517&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 205

EP - 208

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -